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DOI: http://dx.doi.org/10.1016/j.hemonc.2013.06.004Spontaneous regression of malignancies is a very rare phenomenon. Our research of existing
literature yielded only 16 cases of Hodgkin’s lymphoma which regressed spontaneously. The
outcome of primary progressive Hodgkin’s lymphoma is poor even with salvage chemotherapy
and autologous bone marrow transplantation. Here we present a case of primary progressive
Hodgkin’s lymphoma, which regressed spontaneously after failure of salvage chemotherapy. To
our knowledge, this is the first case report of primary progressive Hodgkin’s lymphoma undergoing
spontaneous regression.odgkin’s lymphoma is a cancer of the im-Hmune system that is marked by the presenceof Reed-Sternberg cells. It usually has excel-
lent prognosis with ﬁve-year survival rates exceeding
more than 80%. But the outcome of patients with pri-
mary progressive Hodgkin’s lymphoma (PPHL), de-
ﬁned as progression during induction treatment or
within 90 days after the end of treatment, is dismal.
The complete response (CR) and long term disease
free survival (DFS) – with second line chemotherapy
in a case of PPHL – is 0–10% respectively.1,2 Even
with salvage chemotherapy and autologous stem cell
transplantation, ﬁve-year overall survival (OS) for
these patients is 43%.3
Spontaneous regression (SR) of cancer is the com-
plete or partial disappearance of a malignant tumor
without treatment or in the presence of therapy that
is considered inadequate in exerting a signiﬁcant inﬂu-
ence on neoplastic disease.4 SR in patients with
Hodgkin’s lymphoma is extremely rare. Here we re-
port a case of PPHL in a child who underwent spon-Hematotaneous regression after failure of salvage
chemotherapy. We believe this is the ﬁrst such case
reported in the literature.
CASE REPORT
A 10-year-old girl presented to us in September 2009
with history of fever and cough of two months’ dura-
tion. On examination, she was malnourished with
height of 118 cm weight of 18 kg and body mass in-
dex of 12.9 kg/m.2 The patient had right level 4
lymph nodes measuring 1 cm · 1 cm and splenomeg-
aly of 3 cm below left costal margin. Her chest X-ray
showed mediastinal widening (mediastinal to thoracic
ratio of 0.4). Cervical lymph node biopsy was diagnos-
tic of Hodgkin’s lymphoma, of the nodular sclerosis
type, which was latent membrane protein 1(LMP
1), CD 15 and CD 30 positive (Figure 1a and b).
Contrast CT chest revealed multiple mediastinal
lymphadenopathies with the largest right paratracheal
lymph node measuring 3.7 cm · 3.6 cm. Contrast CTl Oncol Stem Cell Ther 6(3–4) Fourth Quarter 2013 hemoncstem.edmgr.com
Figure 1. (a) H&E · 40 lymph node biopsy showing mono-, bi- to multi-nucleated giant cells of the Reed-Sternberg type. (b) IHC · 40 mono-, bi- to multi-nucleated giant
cells showing CD 30 positivity. (c) H&E · 40 initial bone marrow biopsy before treatment showing normal marrow.
SPONTANEOUS REGRESSION OF HODGKIN'S LYMPHOMA case reportof abdomen revealed retroperitoneal lymph nodes
with mild splenomegaly. The patient’s hemoglobin
was 70 g/L, with total white cells 8.7 · 109/L (neu-
trophils 75%, lymphocytes 20%, monocytes 4%, and
basophils 1%). She had a platelet count of
399 · 109/L. Her total serum protein was 61 g/L
with albumin of 36 g/L, and lactate dehydrogenase
was 1120 U/L. Her bone marrow biopsy did not
show any lymphomatous involvement (Figure 1c).
She was diagnosed with Hodgkin’s lymphoma, nodu-
lar sclerosis stage 3B and was planned for six to eight
cycles of chemotherapy.
She was started on COPP/ABV (cyclophospha-
mide, vincristine, procarbazine, prednisone, doxorubi-
cin, bleomycin, and vinblastine) chemotherapy in
October 2009 and completed a total of eight cycles
of COPP/ABV chemotherapy in May 2010. At the
end of the treatment, she had bilateral axillary lymph
nodes of 1 cm · 1 cm and bilateral inguinal lymph
nodes which measured around 1.5 cm · 1 cm. PET
scan revealed increased uptake in above mentioned
nodes and also sclerotic lytic lesions in D5, D6, D9,
L1 and L5 vertebra. There were lytic lesions in theFigure 2. (a) H&E · 20 bone marrow biopsy after treatment showing num
biopsy showing CD 30 positive giant cells. (c) H&E · 40 bone marrow bio
Hematol Oncol Stem Cell Ther 6(3–4) Fourth Quarter 2013 hemoncstem.edmgr.pelvic bone involving bilateral ilium, left acetabulum,
and the left femur involving the intertrochanteric re-
gion. Bone marrow biopsy showed sheets of atypical
lymphoid cells and small area of ﬁbrosis along with
numerous Reed-Sternberg cells which were CD 15
and CD 30, positively suggestive of involvement of
the bone marrow (Figure 2a and b). The patient
was diagnosed as having primary progressive Hodg-
kin’s lymphoma.
She received four cycles of salvage chemotherapy-
DHAP (dexamethasone, high dose cytarabine and
cisplatin) from August 2010 to October 2010. After
the end of salvage chemotherapy, she had subcenti-
metric axillary lymph nodes and inguinal lymph
nodes. PET scan showed decreased uptake of above
mentioned nodes compared to that performed in
May 2010 but showed new areas of uptake with a
well-deﬁned hypodense lesion in segment 7 of the li-
ver measuring 1.1 cm · 1 cm, nodes involving prever-
tebral and retrocaval regions and persisting bone
lesions (Figure 3a–d). A repeat bone marrow biopsy
showed lymphomatous involvement. The patient
was briefed regarding further options includingerous Reed-Sternberg giant cells suggestive of Hodgkin's lymphoma. (b) IHC · 40 bone marrow
psy taken in March 2012 showing normal marrow.
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Figure 3. (a) PET avid lesion in segment 7 of liver (done in 2010). (b) PET avid nodes involving prevertebral-retrocaval region (done in 2010). (c and d)
PET activity in left ilium and left ischium (done in 2010).
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wanted supportive care only and declined any further
chemotherapy. The patient was discharged from hos-
pital in January 2011.
Surprisingly, the patient reported to our outpa-
tient department 14 months later in March 2012
and was absolutely asymptomatic with weight of
25 kg, height of 125 cm, and BMI of 16. On further
enquiry, she reported no use of chemotherapy agentsHematofrom elsewhere or any alternative form of medicine.
On examination, she had only subcentimetric bilat-
eral inguinal lymph nodes. PET scan repeated
showed complete resolution of the hepatic lesion
and all bone lesions. Nodes in the bilateral inguinal
region and in the prevertebral and retrocaval regions
did not show any metabolic uptake (Figure 4a–d).
Bone marrow biopsy was normal (Figure 2c). The
patient was kept under close observation andl Oncol Stem Cell Ther 6(3–4) Fourth Quarter 2013 hemoncstem.edmgr.com
Figure 4. (a and b) Complete resolution of hepatic lesion and prevertebral-retrocaval node (done in 2012). (c and d) PET showing resolution of ilium
and ischial lesions (done in 2012).
SPONTANEOUS REGRESSION OF HODGKIN'S LYMPHOMA case reportfollow-up. The last follow-up was in January 2013.
Clinically, she is free of lymphadenopathy and is
attending school regularly.DISCUSSION
Primary regression of cancer was ﬁrst described by Sir
William Osler in the early 20th century.5,6 The
frequency of spontaneous regression of cancer isHematol Oncol Stem Cell Ther 6(3–4) Fourth Quarter 2013 hemoncstem.edmgr.estimated to be about 1 per 100,000 patients.
Common cancers undergoing spontaneous regression
include renal cell carcinoma, malignant melanoma,
neuroblastoma, leukemia and non-Hodgkin’s lym-
phoma.2 Among the lymphomas, spontaneous regression
has been reported mostly in patients with low-grade
non-Hodgkin’s lymphoma7,8 but some cases of regression
among intermediate or high-grade non-Hodgkin’s lym-
phomas have also been reported.9,10com 115
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Although the exact mechanism of SR remains un-
clear, various mechanisms have been proposed to ex-
plain this phenomenon. These include immunologic
factors, concomitant infections, hormonal factors, ge-
netic factors, elimination of carcinogens, surgical trau-
ma of the primary tumor, and induction of
differentiation.11 Spontaneous regression of cancer is
most commonly attributed to immunological
factors.12,13
Drobyski and Qazi suggest that most SR cases in
B-cell lymphoma are due to immunological mecha-
nisms.14 SR following infections suggests that infec-
tions trigger immune responses which may cause
spontaneous regression.14 In the post-organ trans-
plant setting, the SR of tumors, which occurs on stop-
ping immunosuppressants, is also indirect evidence
for immune induced spontaneous regression.15 One
more important mechanism that has been proposed
is cytokine induced spontaneous regression.13
SR of Hodgkin’s lymphoma is extremely uncom-
mon and only 16 cases have been reported in the lit-
erature. Among the 16 reported cases of SR, most
were of the mixed cellularity subtype, while ﬁve cases
occurred in children following measles infection.HematoHowever, all ﬁve of these patients still required treat-
ment with chemotherapy following the regression.16,17
In four of these cases, spontaneous regression was
thought to be due to abscopal effect, which is the
regression of lymph nodes that are outside the radia-
tion ﬁeld.18 Our patient had the nodular sclerosis type
of Hodgkin’s lymphoma and there was no history of
serious infections, genetic factors, hormone or radia-
tion exposure which might have caused the spontane-
ous regression of cancer.
Our patient is a 10-year-old child who is a case of
primary progressive Hodgkin’s lymphoma, and who
had spontaneous regression of the disease. She is
doing well even after a two-year treatment-free period.
This case report is a clear example that mechanisms of
SR in cancer are still not fully understood but with
rapid progress in understanding the disease biology,
we hope to ﬁnd the answer to this unsolved question
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